Clinical trials: Psychotic Disorders, open to volunteers
Schizophrenia
Anti-Inflammatory Challenge in Schizophrenia
This study aims to illuminate the biological underpinnings of negative symptoms in schizophrenia-particularly motivational impairments-by probing the link between systemic inflammation and neural activity in reward-related brain…
- Trial name
- NCT05823532
- Testing
- Infliximab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Schizophrenia Disorders, Major Depression
Non-Coding RNAs Gene Expression in Psychiatric Disorders
This study aims to investigate whether specific non-coding RNAs, molecules involved in the regulation of gene expression, are altered in individuals with psychiatric disorders such as schizophrenia, bipolar disorder, major…
- Conditions
- Schizophrenia Disorders, Major Depression, Bipolar Affective Disorders, Obsessive Compulsive Disorder (OCD)
- Trial name
- PsiRNA26 (NCT07649993)
- Testing
- Reverse Transcription Quantitative Polymerase Chain Reaction
- Where
- 5 sites in Italy
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Carmen Concerto
Psychosis
A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
Antipsychotic drugs are used to treat a range of psychiatric disorders including schizophrenia, bipolar disorders, and psychotic depression.
- Trial name
- MetaboMicrobe (NCT06729671)
- Testing
- Bifidobacterium longum APC1472 hydroxypropylmethylcellulose (HPMC) capsule, maltodextrin
- Where
- 2 sites in Ireland
- Volunteers
- 70 people
- Sponsor
- University College Cork
Schizophrenia and Related Disorders, Major Depressive Disorder
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros.
- Conditions
- Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression
- Trial name
- INTENSIFY (NCT05603104)
- Testing
- Clozapine, Esketamine Nasal Product, Escitalopram
- Where
- Israel
- Volunteers
- 1,254 people
- Sponsor
- Dr. Inge Winter
Psychosis, Cannabis Use
Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis
Canada reports some of the highest rates of cannabis use in our youth and young adult populations, among all the developed countries.
- Trial name
- NCT07001878
- Testing
- Metformin
- Where
- 2 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Nova Scotia Health Authority
Schizophrenia
Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119
This study will consist of 2 parts: Part Ⅰ-in healthy adult subjects, Part Ⅱ-in adult patients with schizophrenia
- Trial name
- NCT06504290
- Testing
- VV119 （in healthy adult subjects）, VV119(in adult patients with schizophrenia)
- Where
- 4 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Bipolar I Disorder, Mania
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or…
- Trial name
- NCT07288320
- Testing
- NBI-1117568
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia
A 20-Year Follow-up of First Episode Psychosis: Longitudinal Effects of Early Treatment Strategies and Relapse
The study aims to address the following questions: 1. Do subgroups defined by early medication choices, relapse, and medication taken over 20 years differ in clinical, cognitive, and functional outcomes? 2.
- Trial name
- NCT07616999
- Where
- China
- Volunteers
- 178 people
- Sponsor
- The University of Hong Kong
Schizophrenia, Schizo Affective Disorder
Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia
This study uses a noninvasive technique called transcranial magnetic stimulation (TMS) to study how hallucinations work in schizophrenia.
- Trial name
- NCT05343598
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Mclean Hospital
Treatment Resistant Schizophrenia, Schizophrenia
Magnetic Seizure Therapy for Schizophrenia - Trial
This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).
- Conditions
- Treatment Resistant Schizophrenia, Schizophrenia, Schizoaffective Disorder
- Trial name
- MAST (NCT06672588)
- Testing
- Magnetic Seizure Therapy (MST), Electroconvulsive Therapy (ECT)
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Centre for Addiction and Mental Health
Clinical High Risk for Psychosis (CHR)
Efficacy of Mindfulness in PREventing Progression to Psychosis in Individuals With an Ultra High Risk for Psychosis
The main objective is to evaluate the efficacy of a group-based mindfulness therapy programme in reducing distress associated with symptoms of UHR (Ultra High Risk) or FEP (first psychotic episode) compared with usual treatment.
- Trial name
- EM-PREPS (NCT06870305)
- Testing
- MBTP : Mindflulness based training for psychosis
- Where
- 2 sites in France
- Volunteers
- 270 people
- Sponsor
- Centre Psychothérapique de Nancy
Paranoia, Psychotic Disorders
Racial Disparities in the Expression of Paranoia
Paranoia is a pattern of thinking in which people feel suspicious or believe others may want to harm them. It can occur in many people, not only those with a mental health diagnosis, and it can affect daily life, relationships…
- Trial name
- NCT07460453
- Testing
- Guided Visual Imagery Task
- Where
- United States
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Indiana University
Schizophrenia / Schizoaffective Disorder, Depression / Major Depressive Disorder
Brain Imaging of Cognition Inn Schizophrenia and Depression
Schizophrenia and depression are among the most disabling disorders in all of medicine. Cognitive deficits play a key role in patients' disability, affecting their capacity to contribute actively to society by sustaining…
- Trial name
- NCT04159662
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Schizophrenia, Schizoaffective Disorder
Integrative Neuro-social Cognitive Strategy Programme for Instilling REcovery (INSPIRE) a Community-Based Cognitive Remediation Trial
Adults with serious mental illnesses (such as schizophrenia and schizoaffective disorders) often experience a range of cognitive difficulties (such as memory, problem solving difficulties) that affect their ability to lead…
- Trial name
- NCT06286202
- Testing
- Cognitive Remediation: Adapted Neuropsychological and Education Approach to Remediation (NEAR), Standard Psychiatric Rehabilitation at Anglican Care Centers
- Where
- 5 sites in Singapore
- Volunteers
- 160 people
- Sponsor
- Singapore Institute of Technology
Apathy, Schizophrenia
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician …
- Conditions
- Apathy, Schizophrenia, Schizophrenia; Psychosis
- Trial name
- NCT06482554
- Testing
- Lumateperone 42 mg, Risperidone 2 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Schizophrenia / Schizoaffective Disorder
Healing Stigma Through Stories
This study is the first phase of the research project. The purpose of this phase is to develop and refine a narrative-based intervention designed to reduce self-stigma among people with schizophrenia.
- Trial name
- NCT07708402
- Testing
- Healing Stigma through Stories
- Volunteers
- 24 people
- Sponsor
- National Yang Ming Chiao Tung University
Schizophrenia
Tolerability of MDMA in Schizophrenia
Impaired social motivation, or "asociality," is a negative symptom of schizophrenia (SCZ) and a cause of significant functional impairment in the illness.
- Trial name
- TMS (NCT05770375)
- Testing
- MDMA 40mg, MDMA 80mg, MDMA 120mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Anya Bershad, MD, PhD
Psychosis, Alcohol Use Disorder
Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis
Psychotic disorders impact 4.6 people per 1000 globally, with approximately 1.5 million Canadians affected. The age of onset for psychotic disorders often begin during the critical years of youth and early adulthood, resulting in…
- Conditions
- Psychosis, Alcohol Use Disorder, Cannabis Use Disorder
- Trial name
- NCT07056894
- Testing
- Action-Based Cognitive Remediation
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Nova Scotia Health Authority
Schizophrenia Disorder, Schizoaffective Disorder
Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder
The Impact of Health Literacy on the Attitudes toward Pharmacological Treatment in Patients with Schizophrenia Spectrum Disorder This interventional study is aimed at: assessing and improving the health literacy and assessing the…
- Conditions
- Schizophrenia Disorder, Schizoaffective Disorder, Psychosis
- Trial name
- NCT07488156
- Testing
- Educational sessions
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Cognitive Functioning, Psychosis
The Effect of Combined Brain Stimulation and Yoga for Improving Cognitive Function in Psychosis
The study examines (1) the effects of active anodal (facilitatory) tDCS and yoga combined intervention on cognitive function, clinical symptoms, and quality of life domains (social function and physical wellbeing) in psychosis…
- Trial name
- NCT07747181
- Testing
- Active tDCS, Yoga
- Where
- Hong Kong
- Volunteers
- 135 people
- Sponsor
- The Hong Kong Polytechnic University